BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hiramatsu T, Yoshizawa J, Miyaguni K, Sugihara T, Harada A, Kaji S, Uchida G, Kanamori D, Baba Y, Ashizuka S, Ohki T. Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation. Pediatr Surg Int 2018;34:443-50. [PMID: 29423589 DOI: 10.1007/s00383-018-4234-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011;2:122-34. [PMID: 21399234 DOI: 10.18632/oncotarget.234] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 8.1] [Reference Citation Analysis]
3 Hung KC, Hsieh PM, Yang KL, Lin KJ, Chen YS, Hung CH. Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration. Oncol Lett 2013;5:852-6. [PMID: 23426142 DOI: 10.3892/ol.2012.1089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Steinberg C, Boudreau S, Leveille F, Lamothe M, Chagnon P, Boulais I. Advanced hepatocellular carcinoma with subtotal occlusion of the inferior vena cava and a right atrial mass. Case Rep Vasc Med 2013;2013:489373. [PMID: 23662245 DOI: 10.1155/2013/489373] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev 2014;8:246. [PMID: 25992234 DOI: 10.4081/oncol.2014.246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
7 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]